Abbott Growth Is Dependent On Full Pipeline, Not Xinlay, CFO Says
Executive Summary
Abbott's sales growth predictions for 2006 do not hinge on FDA approval of Xinlay (atrasentan), the company's investigational prostate cancer therapy, Exec VP-Finance and CFO Thomas Freyman said
You may also be interested in...
Abbott Considering Tricor/Statin Combination On Heels Of Labeling Change
Abbott is considering developing a Tricor/statin combination product, Pharmaceutical Product Group President Jeffrey Leiden said Jan. 18
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials